Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Glycated Hemoglobin Tests See Increasing Use

By LabMedica International staff writers
Posted on 08 Apr 2010
Glycated hemoglobin (HbA1c) testing is one of the success stories of point-of-care (POC) diagnostics, and an area that will experience higher growth rates than other POC tests because of expert recommendations, new cases, and thriving mail-in test sales, according to a new market report. More...


The test measures glucose attached to the blood protein hemoglobin, a well-established analyte related to the long-term evaluation of blood sugar control. Ideally, every insulin dependent diabetic should be tested for HbA1c every three months. The test will show its fastest growth in the United States, and Kalorama Information (New York, NY, USA), a market research company and publisher of the report, estimates some 87% of diabetic patients aged 65 and over have been monitored with an HbA1c test.

"HbA1c tests offer a picture of the patient's blood sugar control over the past two or three months, which can be useful in consulting with the patient,” said Shara Rosen, an analyst for Kalorama Information. "It can be conducted at any time of day without fasting, and the value of hemoglobin glucose varies less than fasting plasma glucose [FPG] values.”

Kalorama estimates the global market for POC HbA1c tests was US$230 million in 2009, but should increase to $350 million by 2013. This growth rate is 50% faster than the average POC testing product, according to the report. The self-testing portion, performed chiefly by mail-in lab services, is only a small percentage of those revenues now, but it is showing faster sales growth than lab-based tests. Kalorama expects mail-in testing to grow at 25% for the next five years.

HbA1c testing products have been available for 20 years and there are several competitors in the market. At least 30 companies now offer HbA1c assays for automated systems--Bio-Rad, Abbott Laboratories, Bayer/Siemens, Beckman Coulter, Siemens, and Roche Diagnostics among them. The market is growing in the United States, but faces challenges worldwide, including high device costs for some diabetic world populations, inadequate consumer education, psychologic and physical discomfort, and patient inconvenience.

In 2009, a committee of experts from the American Diabetes Association, the European Association for the Study of Diabetes, and the International Diabetes Association concluded that the A1C test should be the primary test used to diagnose prediabetes, type 1, and type 2 diabetes. "These recommendations won't impact the use of the established FPG tests immediately, but long-term they have the potential to make a major change in the way diabetes is diagnosed,” according to Rosen.

Kalorama Information supplies independent market research in the life sciences, as well as a full range of custom research services. We routinely assist the media with healthcare topics.

Related Links:
Kalorama Information



New
Gold Member
Clinical Drug Testing Panel
DOA Urine MultiPlex
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Urine Chemistry Control
Dropper Urine Chemistry Control
Gram-Negative Blood Culture Assay
LIAISON PLEX Gram-Negative Blood Culture Assay
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.